Product Description
Hoffmann-La Roche is developing at-527, an Oral HCV-NS5B Inhibitor for Mild or Moderate COVID-19. (Sourced from: https://forpatients.roche.com/en/trials/infectious-diseases/covid-19-pneumonia/study-to-evaluate-the-effects-of-at-527-in-non-hospital-29576.html)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - COVID-19 *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Atea
Company Location: Eastern America
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, Canada, France, Germany, Greece, India, Japan, Korea, Latvia, Malaysia, Mauritius, Mexico, Moldova, Netherlands, Pakistan, Philippines, Poland, Romania, South Africa, South Korea, Spain, Sweden, Thailand, Tunisia, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Atea presented P1 Healthy Volunteers results on 2026-05-29 for Bemnifosbuvir
- Clinical Outcomes Reported - Atea presented P1 Hepatitis C results on 2026-05-27 for Bemnifosbuvir
- Clinical Outcomes Reported - Atea presented P2 Hepatitis C results on 2026-05-29 for Bemnifosbuvir
Highest Development Phases
Phase 3: COVID-19|Hepatitis C, Chronic|Severe Acute Respiratory Syndrome
Phase 2: Hepatitis A|Liver Cirrhosis
Phase 1: Healthy Volunteers|Hepatic Insufficiency|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06911320 |
AT-01B-010 | P1 |
Recruiting |
Kidney Diseases|Hepatic Insufficiency |
2026-05-01 |
50% |
2026-04-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05904470 |
AT-01B-004 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A|Liver Cirrhosis |
2024-12-09 |
41% |
2025-02-08 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06868264 |
C-BEYOND | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
2026-09-01 |
16% |
2025-12-06 |
Primary Endpoints|Treatments|Trial Status |
NCT05629962 |
SUNRISE-3 | P3 |
Completed |
Severe Acute Respiratory Syndrome|COVID-19 |
2024-04-25 |
9% |
2025-06-14 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT06204679 |
AT-01B-005 | P1 |
Completed |
Healthy Volunteers |
2024-08-25 |
12% |
2024-09-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05618314 |
AT-03A-011 | P1 |
Completed |
Kidney Diseases |
2024-06-15 |
50% |
2025-08-27 |
Primary Endpoints|Treatments |
NCT06356194 |
AT-01B-006 | P1 |
Completed |
Healthy Volunteers |
2024-05-30 |
12% |
2024-08-01 |
Primary Endpoints|Treatments|Trial Status |
NCT05724693 |
AT-03A-010 | P1 |
Completed |
Healthy Volunteers |
2024-04-23 |
12% |
2024-08-01 |
Primary Endpoints |
NCT07037277 |
C-Forward | P3 |
Recruiting |
Hepatitis C, Chronic |
2026-12-01 |
6% |
2026-04-14 |
Primary Endpoints|Start Date|Treatments |
2023-504566-28-00 |
AT-01B-004 | P2 |
Completed |
Hepatitis C, Chronic |
2025-01-28 |
2025-05-02 |
Treatments |
|
jRCT2071240070 |
jRCT2071240070 | P3 |
Completed |
COVID-19 |
2024-05-30 |
|||
2023-504540-33-00 |
AT-03A-017 | P3 |
Completed |
COVID-19 |
2024-05-06 |
2025-05-02 |
Treatments |
|
2025-521096-31-00 |
AT-01B-008 | P3 |
Not yet recruiting |
Hepatitis C, Chronic |
2027-03-31 |
|||
NCT07272889 |
EE/LNG | P1 |
Completed |
Healthy Volunteers |
2026-02-17 |
2026-04-14 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06921941 |
AT-01B-009 | P1 |
Completed |
Healthy Volunteers |
2025-07-02 |
50% |
2025-08-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07007806 |
AT-01B-011 | P1 |
Completed |
Healthy Volunteers |
2025-06-28 |
50% |
2025-08-30 |
Primary Endpoints|Start Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/12/2026 |
News Article |
Semrush Unveils New Brand Identity to Command the AI Search Era |
|
01/08/2026 |
News Article |
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference |
|
01/06/2026 |
News Article |
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
|
12/22/2025 |
News Article |
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus |